Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Frequently asked questions
What sector does Relmada Therapeutics, Inc (RLMD) operate in?
Relmada Therapeutics, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Relmada Therapeutics, Inc (RLMD) current stock price?
As of the latest data, Relmada Therapeutics, Inc stock price is $3.23, with a previous close of $3.27. Relmada Therapeutics, Inc lost -$0.04 in the last trading session, representing a -1.22% loss.
What is Relmada Therapeutics, Inc (RLMD) current market capitalization?
Relmada Therapeutics, Inc market cap is approximately 344.54 million.
What is Relmada Therapeutics, Inc (RLMD) Earnings Per Share (EPS)?
The trailing EPS is -$0.91, and the forward EPS is -$0.41.
What is Relmada Therapeutics, Inc (RLMD) EBITDA?
Relmada Therapeutics, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -12.91 million.
Does Relmada Therapeutics, Inc (RLMD) pay dividends?
No. Relmada Therapeutics, Inc does not pay a dividend.
When is Relmada Therapeutics, Inc (RLMD) next earnings report?
Relmada Therapeutics, Inc is expected to release its next earnings report on September 30, 2026.
What is Relmada Therapeutics, Inc (RLMD) beta (volatility) score?
Relmada Therapeutics, Inc has a beta of 0.513, indicating lower volatility than the overall market.
